|
Market Cap (3-Jul) $2,416,092 (1,016th) |
Close (30-Jun) $0.016 |
Volume (30-Jun) 5,525,026 |
Shortsold (24-Dec) 11,970 (0.01%) (590th) |
|
52w High $0.082 |
52w Low $0.011 |
P/E - |
EPS -0.05 |
IBX released this announcement to the ASX on 16 December 2020, 8:40. The announcement is not marked as price sensitive, and is 1 page(s) in length and 105.3kb in size.
You can view all announcements from IBX and see how they appear on a price chart on the announcements page.
At the date of this announcement, IBX was 0.047% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 590th as of the latest reported data (24 December 2024).
| Other Recent Announcements from IBX | |
|---|---|
| Expanded collaboration with Siemens Healthineers to US | 28 June 2023, 8:49 |
| Imagion to complete the MagSense HER2 Phase 1 Study | 21 June 2023, 8:27 |
| Imagion Announces New CEO | 19 June 2023, 8:31 |
| First-in-human study update - Study open for enrolment | 16 December 2020, 8:40 |
| Issue of Rights & Options under EIP | 15 December 2020, 12:25 |
| Appendix 3G | 15 December 2020, 12:23 |
| Resignation and Appointment of Company Secretary | 8 December 2020, 9:25 |
You must be logged in to post a reply.
Imagion Biosystems 